In the sub-acute phase of Chikungunya virus disease, clinical management is guided by the phase of the disease. The main objective is to alleviate pain and stop the progression of inflammation. When an oral corticosteroid regimen does not achieve adequate control, a structured next-line protocol applies.
The previous line used oral corticosteroids (prednisone). Escalation to this protocol is indicated when that regimen failed to achieve:
For patients with localised tendon or joint involvement — such as tenosynovitis, bursitis, or synovitis — that has not responded adequately to oral therapy, a targeted local intervention is considered. The full protocol defines the specific indications, selection criteria, and approach.
The clinical management of Chikungunya is based on the phase of the disease.
The main objective of management during this phase is to alleviate pain and stop the progression of inflammation.
Corticosteroid infiltration may be helpful in cases of tenosynovitis, bursitis, and synovitis inadequately treated by oral therapy.
View source ↗